NASDAQ · Biotechnology
XERS (XERS) Stock
$8.19
+0.74%
NASDAQ: XERS
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?
Zacks · Jul 8, 2026
Xeris Biopharma Holdings Insider Sold Shares Worth $383,176, According to a Recent SEC Filing
MT Newswires · Jul 7, 2026
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Business Wire · Jul 3, 2026
Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity?
Insider Monkey · Jun 30, 2026
Xeris Biopharma Appoints CEO John Shannon Board Chair
MT Newswires · Jun 30, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held3.38%
Institutions Held62.61%
Institutions Float Held64.80%
Peer Comparison
About XERS
XERS is led by CEO John Shannon, publicly traded since 2018.
XERS stock trades at $8.19 with a market capitalization of $1.41B. The stock is valued at a price-to-earnings (P/E) ratio of 89.43, price-to-book of 76.34, price-to-sales of 3.43. Over the past 52 weeks the stock has ranged between $4.40 and $10.08, and currently trades 18.8% below its 52-week high.
On profitability, XERS generates a return on equity (ROE) of 80.95% — well above the market average, a sign of a high-quality business, return on capital employed of 178.57%, an operating margin of 11.40%, a net profit margin of 3.81%.